You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

ID: 11-5 Sep 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Sarcoma Disease Site Group

Research Question(s)

  1. In patients with inoperable locally advanced or metastatic soft tissue sarcoma, does firstline dose-intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation improve response rate, time-to-disease progression, or survival, compared with standard-dose chemotherapy?
  2. What are the effects of first line dose-intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation on toxicity and quality of life?

For the purposes of this practice guideline, “dose-intensive chemotherapy” is defined as regimens administered with the intent to increase standard doses of chemotherapy, supported by the use of hematopoietic growth factors and/or autologous bone marrow/stem cell transplant support. Standard chemotherapy includes regimens that have been previously evaluated in a large phase II trial or a randomized phase III trial without growth-factor support.

pdf download Full Report (PDF) (700.14 KB)